Kaveri Pohlman
Stock Analyst at Clear Street
(3.41)
# 2,343
Out of 5,078 analysts
232
Total ratings
33.9%
Success rate
4.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Reiterated: Buy | $220 | $125.10 | +75.86% | 4 | Oct 20, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $47 → $22 | $21.00 | +4.76% | 3 | Oct 6, 2026 | |
| QTTB Q32 Bio | Initiated Coverage: Buy | $38 | $8.65 | +339.31% | 1 | Oct 1, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $28 | $9.58 | +192.28% | 5 | Sep 30, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $131 | $80.15 | +63.44% | 5 | Sep 23, 2026 | |
| EVMN Evommune | Reiterated: Buy | $28 → $23 | $5.10 | +350.98% | 4 | Sep 9, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $99 | $21.19 | +367.20% | 3 | Sep 8, 2026 | |
| JBIO Jade Biosciences | Rated: Buy | $25 → $48 | $14.59 | +228.99% | 3 | Sep 4, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $173 | $138.43 | +24.97% | 7 | Aug 31, 2026 | |
| LBRX LB Pharmaceuticals | Rated: Buy | $45 → $69 | $38.73 | +78.16% | 2 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $47 | $14.37 | +227.07% | 20 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $55 → $68 | $41.52 | +63.78% | 3 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.23 | +631.71% | 2 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $31 | $15.47 | +100.39% | 1 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $11.85 | +490.72% | 6 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $29 | $12.61 | +129.98% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $533 → $680 | $434.24 | +56.60% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.33 | +802.26% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $14.39 | +38.99% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $16.66 | -27.97% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $7.31 | +146.24% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.36 | +435.71% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.57 | +162.58% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $64.53 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $43.79 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.25 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.68 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $18.54 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.46 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.49 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.18 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $1.46 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $2.32 | n/a | 3 | Jul 6, 2022 |
Palvella Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $220
Current: $125.10
Upside: +75.86%
ArriVent BioPharma
Oct 6, 2026
Reiterated: Buy
Price Target: $47 → $22
Current: $21.00
Upside: +4.76%
Q32 Bio
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $8.65
Upside: +339.31%
Sagimet Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $28
Current: $9.58
Upside: +192.28%
Oruka Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $131
Current: $80.15
Upside: +63.44%
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $28 → $23
Current: $5.10
Upside: +350.98%
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $99
Current: $21.19
Upside: +367.20%
Jade Biosciences
Sep 4, 2026
Rated: Buy
Price Target: $25 → $48
Current: $14.59
Upside: +228.99%
Protagonist Therapeutics
Aug 31, 2026
Reiterated: Buy
Price Target: $173
Current: $138.43
Upside: +24.97%
LB Pharmaceuticals
Aug 21, 2026
Rated: Buy
Price Target: $45 → $69
Current: $38.73
Upside: +78.16%
Aug 14, 2026
Rated: Buy
Price Target: $46 → $47
Current: $14.37
Upside: +227.07%
Aug 6, 2026
Rated: Buy
Price Target: $55 → $68
Current: $41.52
Upside: +63.78%
Aug 3, 2026
Reiterated: Buy
Price Target: $9
Current: $1.23
Upside: +631.71%
Aug 3, 2026
Reiterated: Buy
Price Target: $31
Current: $15.47
Upside: +100.39%
Jun 22, 2026
Reiterated: Buy
Price Target: $70
Current: $11.85
Upside: +490.72%
May 7, 2026
Reiterated: Buy
Price Target: $21 → $29
Current: $12.61
Upside: +129.98%
May 6, 2026
Reiterated: Buy
Price Target: $533 → $680
Current: $434.24
Upside: +56.60%
Mar 31, 2026
Reiterated: Buy
Price Target: $12
Current: $1.33
Upside: +802.26%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $14.39
Upside: +38.99%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $16.66
Upside: -27.97%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $7.31
Upside: +146.24%
Dec 1, 2025
Reiterated: Buy
Price Target: $18
Current: $3.36
Upside: +435.71%
Nov 26, 2025
Reiterated: Buy
Price Target: $12
Current: $4.57
Upside: +162.58%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $64.53
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $43.79
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.25
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $1.68
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $18.54
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $11.46
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $5.49
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $25.18
Upside: n/a
Apr 29, 2024
Reiterated: Buy
Price Target: $21
Current: $1.46
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $2.32
Upside: n/a